Correction to: Targeted Oncology https://doi.org/10.1007/s11523-023-01016-x


In Table 1 Summary of PARPis approvals by the FDA and EMA regulatory agencies, in the first column


“Talazoparib + abiraterone”


should read


“Talazoparib + enzalutamide”.


The original article has been corrected.